DITROPAN XL Rx
Generic Name and Formulations:
Oxybutynin chloride 5mg, 10mg, 15mg; ext-rel tabs.
Janssen Pharmaceuticals, Inc.
Indications for DITROPAN XL:
Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Neurologic detrusor overactivity symptoms in children.
Swallow whole. Take with fluid. Initially 5mg or 10mg once daily; may increase weekly in 5mg increments; max 30mg/day.
<6yrs: not recommended. ≥6yrs: Swallow whole. Take with fluid. Initially 5mg once daily; may increase in 5mg increments; max 20mg/day.
Urinary or gastric retention; uncontrolled narrow-angle glaucoma; or patients at risk for these.
Discontinue if angioedema develops; consider discontinuing if anticholinergic CNS effects occur. Bladder outflow or GI obstruction. Ulcerative colitis. Intestinal atony. GERD. GI narrowing or stricture. Pre-existing dementia. Parkinson's disease. Myasthenia gravis. Decreased GI motility in those with autonomic neuropathy. Exposure to high environmental temperatures. Hepatic or renal impairment. Pregnancy (Cat.B). Nursing mothers.
Increased drowsiness with alcohol, other CNS depressants. Additive anticholinergic effects with other anticholinergics. May be potentiated by CYP3A4 inhibitors. Decreases GI motility, possibly affecting absorption of other drugs. Caution with drugs that can cause or exacerbate esophagitis (eg, bisphosphonates).
Dry mouth, constipation, somnolence, headache, diarrhea, nausea, tachycardia, blurred vision, dry eyes, other anticholinergic effects.
Clinical Pain Advisor Articles
- Manual Therapy vs Opioids for Management of Shoulder, Spine Pain
- Opioids: Clinician Concern and Prescribing Practices
- Screening for Hyperglycemia Prior to Steroid Injections for Chronic Pain
- Ensuring Safety During Long-Term Opioid Therapy
- Intervention by Pharmacists May Effectively Reduce Use of Inappropriate Medications in the Elderly
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Business Degree Increasingly Useful for Doctors
- PainDETECT May Not Be Optimal to Detect Neuropathic Components of Orofacial Pain
- Kinesiophobia May Be Associated With Greater Cutaneous Allodynia in Migraine
- CDC: 8.8% of Individuals in the United States Uninsured in First Half of 2018
- Patient Experiences Shed Light on Diagnostic Errors
- Topical Migraine Trigger Point Treatment as Effective as Injection
- Wikipedia in Medical Education: An Educator's Guide to Crowdsourcing